This project has successfully adapted an isolated perfused gill model specifically to Atlantic salmon and has provided in vitro results of gill function and branchial vascular resistance in AGD-affected animals. This model represents a novel in vitro method for AGD research.

09/01/2013

Scientists at the Institute for Marine and Antarctic Studies have completed a two year experimental project on a globally emerging fish disease. Dr Mark Adams and co-investigators Dr Andrew Bridle and Professor Barbara Nowak investigated the comparative susceptibility and host responses of various endemic and salmonid fishes to amoebic gill disease (AGD).

02/01/2016

Before this project our knowledge of immune response in Amoebic Gill Disease (AGD) was fundamentally limited and more information was required to assess the potential for immunomodulators in the management of AGD.

10/01/2007

The most significant outcome of this project is the commencement in July 2007 of sea trials for the experimental DNA vaccine made up of six antigens shown to provide a relative increase in protection of approximately 40 percent in laboratory based amoebic gill disease (AGD) trials.

06/01/2008

Ambient environmental conditions mean that the Tasmanian salmon industry will always suffer from high maturation rates due to its high water temperatures and increased light intensity. Additional artificial lighting in Tasmania has been shown to reduce maturation by up to 30%; increase growth rates significantly; and delay maturation by 8 weeks (Porter et al., unpublished).

06/01/2009

There is an urgent need to develop novel treatments which would reduce the impact of AGD on salmon industry. A detailed benefit – cost analysis for the AQUAFIN CRC AGD project was undertaken which gave a Net Present Value of the economic benefit of $21.6M, Benefit/Cost Ratio of 5.3.

01/01/2005

This project primarily addresses physiological "robustness" in Atlantic salmon. Critical issues for the Tasmanian salmon industry include understanding the physiological response of salmon to hypoxia due to decreased dissolved oxygen (DO) and increases in other dissolved metabolic wastes.

01/01/2011

Amoebic Gill Disease (AGD) is one of the most serious health issues for the Tasmanian salmonid farming industry and significantly increases production costs of Atlantic salmon in Tasmania (Nowak et al 2002).

01/01/2011

Amoebic gill disease (AGD), caused by the pathogenic free living protozoan Neoparamoeba perurans is the most significant health issue currently affecting the production of Tasmanian Atlantic salmon Salmo salar.

01/01/2013